Annexin A3 Antibodies

Annexin A3 (ANXA3)

Inhibitor of phospholipase A2, also owns anti- coagulant properties. Also cleaves the cyclic bond of inositol 1,2-cyclic phosphate to form inositol 1-phosphate.

.

Gene Information

Human
Gene Name:	ANXA3
Uniprot:	P12429
Entrez:	306

Family

Belongs to:
annexin family

Alternative Names

35-alpha calcimedin; Annexin A3; annexin A3,1,2-cyclic-inositol-phosphate phosphodiesterase; Annexin III; annexin-3; ANXA3; Calcimedin 35-alpha ; calcimedin 35-alpha; Lipocortin III; PAP-III; Placental anticoagulant protein III; placental anticoagulant protein III, calcimedin 35-alpha

Molecular Weight

Mass (kDA):
36.375 kDA

Genomic Context

Human
Location:	4q21.21
Sequence:	4; NC_000004.12 (78551761..78610447)

Diseases

• Malignant Neoplasms
• Neoplasms
• Prostatic Neoplasms
• Malignant Neoplasm Of Prostate
• Carcinoma
• Inflammation
• Colorectal Neoplasms
• Colorectal Cancer
• Tissue Adhesions
• Autoimmune Reaction
• Neoplasm Metastasis
• Intraepithelial Neoplasia

• Metastatic Malignant Neoplasm To The Lymph Node
• Renal Cell Carcinoma
• Rheumatoid Arthritis
• Adenocarcinoma
• Ischemia
• Prostatic Intraepithelial Neoplasias
• Autoimmune Diseases

Pathways

• Cell Adhesion
• Transport
• Cell Proliferation
• Cell Death
• Cell Migration
• Osteoblast Differentiation
• Immune Response
• Tube Formation
• Chondrocyte Differentiation
• Inflammatory Response
• Phagocytosis
• Translation
• Cell Cycle

• Cell Motility
• Liver Regeneration
• Exocytosis
• Regulation Of Cell Cycle
• Glycosylation
• Immunoglobulin Production
• Amine Transport

PTMs

• Phosphorylation

• Glycosylation

• Acetylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/ANXA3

Boster Bio - Best Uses Of The ANXA3 Marker

If you've been wondering what Boster Bio's Anti-Annexin 3 (Y64) Marker is all about, read this article. We'll talk about the detection methods and applications of this unique marker. Plus, we'll cover the various types of studies that may use it. So, get ready to be amazed! Let's get started! First, let's review the ANXA3 protein.

Boster Bio's Anti-Annexin 3 (Y64) ANXA3 Marker

The anti-Annexin 3 (Y64) marker from Boster Bio reacts with Human, Mouse, Rat and Rhesus monkey serum. It is highly specific and has a lower limit of quantification of 1ng/mL. The assay is available for both human serum and post-DRE urine samples. The anti-Annexin 3 (Y64) marker is compatible with various ELISA assays, which makes it a useful companion to the other ANXA3 markers.

ANXA3 is a key player in proliferative signaling in cancer cells. In addition to facilitating cancer cell proliferation, ANXA3 is also required for the invasion of the tumor cells. The expression of ANXA3 is associated with poor clinical outcomes for cancers of the breast and other types, including ovarian, lung and breast adenocarcinomas. Activation of the Notch and MAPK/ERK/JNK signaling pathways may contribute to tumor cell proliferation and invasion. However, ANXA3 is a potential diagnostic and prognostic marker for cancer.

The ANXA3 protein contains 5 a-helices in each structural domain. ANXA3 also contains ethanolamine and sulfate ions. ANXA3 is implicated in tumor proliferation, invasion, and resistance to chemotherapeutic agents. However, further research is required before the marker is considered clinically useful.

The ANXA3 protein is important for regulating the expression of several physiological processes, including cell division, differentiation, motility, angiogenesis, apoptosis, and apoptosis. It is a potential candidate biomarker for cancer and could be a promising therapeutic target. Several studies suggest that the ANXA3 gene is differentially expressed in different types of cancer. Furthermore, its differential expression in cancer cells is associated with invasion, metastasis, and angiogenesis.

While there are no data on the factors responsible for downregulated expression of ANXA3, the expression of ANXA3 has been shown to be associated with the progression of cancer. The ANXA3 protein has anti-oncogenic activity in thyroid neoplasms. It may also be useful as a prognostic marker to support population risk stratification.

In addition to ANXA3 being a novel marker of adult microglia, this study also provides valuable information about the phospholipase A3 receptor. Using this marker to identify microglial cells will further enrich our understanding of this protein's role in the CNS. The published article contains all data generated during the study. The animal experiments were approved by the Ethics Committee of the Xiangya Hospital of Central South University. The authors declare no competing interests.

Detection Methods

Detection methods for the ANxA3 marker include the use of monoclonal antibodies directed against novel epitopes. The preferred monoclonal antibodies are tgc5 ProII 6G7 and tgc5 ProIII 1611. The latter two are directed against a specific epitope found in SEQ ID NO:5.

Previous ANXA3 determination methods suffer from low specificity due to substantial cross-reactivity with other annexins. The present invention aims to provide a highly specific ANXA3 marker for diagnostic purposes. The invention describes a method for detecting annexin A3 in urine samples. This method can be used to diagnose prostate cancer or benign prostate hyperplasia.

A proposed IRUS uses a FET biosensor with a disposable sensing gate for detection of the ANXA3 antigen in urine samples. The IRUS detects ANXA3 at concentrations of 1 fg/mL with high reliability. Furthermore, ANXA3 levels in urine show a clinically significant correlation with actual tumor volumes. Furthermore, this IRUS provides a roadmap to the development of a clinically-ready noninvasive platform that can detect and predict prostate cancer in men without a DRE.

Transwell assays were also performed to evaluate ANXA3 function. Knockdown of ANXA3 expression inhibited the invasion of GC cells, while overexpression of ANXA3 increased invasion. Furthermore, double knockdown of ANXA3 and IkBa inhibited the growth of ALDH+ cells. They showed little effect on the ALDH+ population.

ANXA3 is a tumor oncogene in various common human cancer types, including colon and breast cancer. Its overexpression in ovarian cancer cells inhibits p53 and enhances platinum-drug resistance. Other studies have shown that ANXA3 serves as a tumor oncogene in colorectal, pancreatic, and prostate cancers. ANXA3 has important implications for the treatment of hepatocellular cancer.

Immunohistochemical analysis of 183 human GC samples was used to study ANXA3 protein expression. This procedure was similar to those described previously. Two observers reviewed formalin-fixed paraffin-embedded sections and scored them based on the percentage of tumor cells that were positively stained and the intensity of the staining. Detection methods for the ANXA3 marker clearly show that ANXA3 is a cancer marker that can help distinguish between benign and malignant GC cells.

The ANXA3 marker plays an important role in GC metastasis, and overexpression of the gene increases tumorigenicity. Moreover, ANXA3 has been shown to regulate cell migration and invasion. It also has important roles in the expression of vimentin, which is a hallmark of EMT. Further studies of the role of ANXA3 in EMT are necessary to understand how it contributes to the development of metastatic GC.

Detection methods for the ANxA3 marker comprise three-dimensional gel electrophoresis, a phospholipid-based immunohistochemistry assay, and a mRNA-based PCR-based assay. Both of these methods offer robust and cost-efficient diagnosis. In addition, both methods require amplification of mRNA molecules that contain a large number of mRNAs.

Applications

The ANXA3 marker has been demonstrated to play an important role in the development, metastasis, drug resistance, and therapy of tumors. Indeed, up-regulation of this gene is associated with increased drug resistance of ovarian carcinoma. Moreover, up-regulation of this gene has been associated with the development of pancreatic, colorectal, and prostate carcinoma. Therefore, these studies suggest that ANXA3 serves as a tumor oncogene.

The expression of ANXA3 is higher in breast cancer cell lines, and knockdown of ANXA3 inhibits colony-forming ability and proliferation in MDA-MB 231 cells. ANXA3 expression in tumours has also been examined in a nude mouse model of a subcutaneous tumour. The transfection group showed significantly lower tumour volume, lower proliferative rate, and higher G0/G1 cell ratio than the control group.

ANXA3 has been found to induce the expression of VEGF in tumors. Furthermore, it is known to interact with HIF-a, and high ANXA3 expression promotes colon cancer development and metastasis. This protein may also induce angiogenesis via HIF-a signalling. Thus, ANXA3 expression is of great interest in colon cancer and may be a useful biomarker in colon cancer research.

Furthermore, ANXA3 expression levels in prostate cancer samples were higher than in healthy controls. Further studies are necessary to identify the molecular mechanisms underlying the ANXA3 marker's role in gastric cancer. However, these data indicate that ANXA3 has a useful role in diagnosing various disease states. Further research is needed to determine the molecular mechanisms by which ANXA3 contributes to the progression of gastric cancer.

Interestingly, ANXA3 regulates gastric cancer cell migration, invasion, and metastasis. It is also known to regulate the expression of vimentin, a marker of EMT. It is thought to play a significant role in cellular migration. This suggests that ANXA3 may serve as a potential therapeutic target for gastric cancer patients. Our study was conducted on gastric cancer cell lines obtained from the Chinese Academy of Sciences' Committee of Type Culture Collection. The cells were cultured in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum. The cells were maintained at 37degC and 5% CO2.

Furthermore, the ANXA3 gene expression level is associated with an increase in the amount of antibody-producing B-cells in the blood. Antibodies directed against this gene are an excellent therapeutic target for hepatocellular cancer. For this reason, antibodies directed against this gene are a crucial component of hepatocellular carcinoma research. While the ANXA3 gene is widely used, a more precise definition is needed.

The ANXA3 gene is located on human chromosome 4q13-q22. Its gene is closely related to ANXA5 and ANXA8, which are highly homologous. Interestingly, ANXA3 and ANXA5 share the same sequence of four conserved domains. These three proteins are closely related in structure and function. The annexins are highly regarded as important components of cellular differentiation. Their expression may also play a role in drug resistance and cancer treatment.